Long noncoding RNAs (lncRNAs) are defined as processed transcripts longer than 200 nucleotides that do not encode for proteins. Thus far, >100 000 lncRNA genes have been defined in the human genome, which far outnumber all protein-coding and microRNA genes combined, suggesting a dominant role of this class of genes in the mammalian genome. 15 Indeed, accumulating evidence has demonstrated that lncRNAs function as important regulators in stem cell pluripotency, 16 cellular differentiation, 17, 18 cell cycle progression, 19 and human diseases. 20 Unlike microRNAs, which exhibit well-defined actions in negatively regulating gene expression by targeting the 3′-untranslated region of transcripts, lncRNAs display diverse and unpredictable regulatory roles. 18, 21, 22 In this context, although numerous lncRNAs have been intensively investigated in the stem cell and cancer fields, studies of lncRNA in vascular biology and disease are only beginning to be undertaken. 20, 23 Lnc-Ang362 (aka HG-MIR222) was the first VSMC lncRNA discovered by RNA-seq analysis. 24 This lncRNA was shown to be elevated in rat aortic SMCs after angiotensin II stimulation, and it seems to regulate VSMC proliferation via controlling levels of miR221/222. 24 The p53-induced LncRNA-p21 was found to have a role in suppressing the progression of atherosclerosis in the apolipoprotein E null mouse by repressing VSMC proliferation and inducing apoptosis. 25 A smooth muscle and endothelial cell-enriched lncRNA called SENCR was revealed to play a role in maintaining VSMC contractile phenotype and concomitantly inhibiting VSMC migration. 17 Although lncRNAs tend to be more tissue specific, none of the aforementioned lncRNAs exhibit a strict VSMC-specific expression profile. Moreover, whether there is interplay between these or other unknown lncRNAs and the regulatory axis of MYOCD-SRF is unknown.
We hypothesized there must exist inducible VSMCspecific lncRNAs comprising a new layer of molecular regulation of the VSMC contractile phenotype. To this end, we used RNA-seq in MYOCD-overexpressing human coronary artery SMCs (HCASMCs) to identify new lncRNAs regulated in a CArG-SRF-MYOCD-dependent manner. Several lncRNAs were revealed to be induced or repressed by MYOCD. Here, we report on a new lncRNA we named, MYOcardininduced Smooth muscle LncRNA, Inducer of Differentiation (MYOSLID). We demonstrated that MYOSLID is a VSMCselective lncRNA, which is a direct transcriptional target of MYOCD/SRF and transforming growth factor-β (TGFβ)/ SMAD pathways. Most importantly, we defined a critical role of MYOSLID in amplifying the VSMC differentiation program, likely through feed-forward actions of MYOCD-related transcription factor A (MKL1) and TGFβ-SMAD pathways.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

MYOSLID Is a MYOCD-Inducible and VSMC-Selective Natural Antisense lncRNA
Cultured VSMCs exhibit reduced expression of MYOCD and various contractile genes with acquisition of the synthetic phenotype. 6 To induce a VSMC contractile phenotype similar to that in the intact vessel wall, we transduced HCASMCs with adenovirus carrying MYOCD, a potent SRF cofactor for the VSMC differentiation program. 26 We performed RNA-seq under these conditions to define novel lncRNAs associated with VSMC differentiation. As expected, RNA-seq revealed the induction of many MYOCD/SRF target genes, such as MYH11, ACTA2, and CNN1 (data not shown). A total of 265 lncRNAs were found to be expressed in HCASMCs, among which, 54 were annotated lncRNAs in the UCSC Genome Browser and the remaining were novel lncRNAs. One hundred thirty-seven lncRNAs were significantly regulated by MYOCD with 79 upregulated and 46 downregulated (fragments per kilobase of transcript per million mapped reads fold change ≥2, Figure 1A ). We selected 13 lncRNAs (8 upregulated and 5 downregulated), named here as MYOCD-lncRNAs, exhibiting the highest change in fragments per kilobase of transcript per million mapped reads expression ( Figure 1B ) and validated each by quantitative reverse transcription polymerase chain reaction (qRT-PCR; Figure 1C ). We examined the expression profile for all 13 validated MYOCD-lncRNAs in different human cell culture models and human tissues (data not shown). MYOSLID (previously AC007879.7) is enriched in 3 independent HCASMC isolates and in the VSMC cell line, HITB5 ( Figure 1D ). MYOSLID is also selectively expressed in blood vessels (artery and vein) and bladder ( Figure 1E ) but not in other tissues with a paucity of SMC. The VSMC-selective expression profile is similar to LMOD1, a previously characterized VSMC-specific gene. 8 Although transcripts of all 13 MYOCD-lncRNAs are not conserved in mouse genome, they share high conservation with primates such as Rhesus monkey and Chimp, indicating that transcripts of these MYOCD-lncRNAs are unique to these animals (data not shown). These data identify MYOSLID as a novel MYOCD-induced and smooth muscle-selective lncRNA.
MYOSLID is located in an lncRNA-rich genomic region of chromosome 2 where the closest protein-coding genes are 70 kb (KLF7) and 200 kb (CREB1) away from its 5′ end and 3′ end, respectively (Figure IA in the online-only Data Supplement). Two splice variants of MYOSLID were annotated in the UCSC Genome Browser. Interestingly, the entire MYOSLID locus falls within an opposing transcribed lncRNA (LOC101927865) with partially overlapping exonic sequence ( Figure 1F ). Thus, MYOSLID is best classified as a natural antisense lncRNA. 23 the proximal promoter region of MYOSLID. Another natural antisense lncRNA, AC007879.5, also partially overlaps with MYOSLID ( Figure 1F ). Expression levels of LOC101927865 and AC007879.5 are much lower than MYOSLID, and there is no detectable level of AC007879.3 in HCASMCs (data not shown). Furthermore, none of these 3 lncRNAs can be induced by MYOCD or TGFβ1 ( Figure IB and IC in the online-only Data Supplement). The presence of H3K4Me1, H3K4Me3, and H3K27Ac histone marks within the −2 kb region of MYOSLID indicates this region likely harbors an active promoter for MYOSLID. Interestingly, sequence analysis shows 3 computerpredicted CArG boxes in the putative MYOSLID promoter. Furthermore, chromatin immunoprecipitation-seq data of HCASMCs (manuscript in preparation) support the presence of SRF binding in the same region ( Figure 1F ). Collectively, these data define MYOSLID as a natural antisense lncRNA that may be a direct target of the MYOCD/SRF/CArG triad. KLF7 is the nearest protein-coding gene located 73.8 kb upstream of MYOSLID and transcribed in an antisense orientation to MYOSLID ( Figure IA in the online-only Data Supplement).
Genomic analysis and chromatin immunoprecipitation-seq for SRF binding in HCASMCs revealed 3 putative CArG boxes in the proximal promoter region of KLF7 (data not shown). KLF7 is also strongly induced by MYOCD in HCASMCs ( Figure ID in the online-only Data Supplement). Depletion of MYOSLID by 2 different dicer substrate siRNAs (D-siRNAs) in HCASMCs did not change mRNA levels of KLF7 and 2 other neighboring lncRNAs ( Figure IE and IF in the online-only Data Supplement), suggesting no cis or trans effect of MYOSLID on the expression of these neighboring genes. Thus, the induction of KLF7 by MYOCD is probably through its own CArG-containing promoter.
We performed Rapid Amplification of cDNA end to define the full-length sequence of both MYOSLID variants. We extended >500 bp at the 3′ end, identifying a small portion of exon 2 (78 bp) and an additional new exon in MYOSLID_V1, exon 3 (422 bp; Figure 1G ). We were unable to extend the 5′ end of MYOSLID_V1, indicating a complete 5′ end of MYOSLID_V1 as annotated in GenBank. However, we extended the original exon 1 of MYOSLID_V2 to an additional 161 bp and confirmed that Figure 1G ). Finally, we PCR amplified both variants and confirmed the entire 1305 bp of the MYOSLID_V1 sequence based on the original annotation and the rapid Amplification of cDNA end results. However, sequencing results of MYOSLID_V2 revealed a misannotated small intron 1 with the original annotation, which is actually included in exon 1 of MYOSLID_V2 ( Figure IIA and IIB in the online-only Data Supplement). Furthermore, using multiple variant-specific primer pairs, we confirmed that both variants were induced by MYOCD ( Figure 
MYOSLID Is a Cytoplasmic lncRNA
Insight into the function of lncRNAs can be predicted by their localization in a cell. 23 Conventional RT-PCR analysis of the fractionated RNA from cytosolic and nuclear compartments in HCASMCs revealed that MYOSLID transcripts were predominately localized in the cytosol, a pattern similar to SENCR, a known cytosolic lncRNA, 17 and the mRNA of the protein-coding gene, GAPDH (Figure 2A ). MYOCD was able to induce both cytosolic and nuclear MYOSLID while it failed to promote the expression of SENCR ( Figure 2B ). Consistent with the qRT-PCR data, RNA-FISH documented the majority of MYOSLID transcripts in the cytosol with few transcripts seen in the nucleus. In contrast to the abundant signal of PP1B mRNA, the basal level of MYOSLID was much lower, consistent with the low abundance of most lncRNAs compared with proteincoding genes. 19 In agreement with the qRT-PCR results, when HCASMCs were treated with Ad-MYOCD, both cytosolic and nuclear MYOSLID signals were increased ( Figure 2C 
MYOSLID Is a Direct Transcriptional Target of MYOCD/SRF
Data above suggest that MYOSLID could be a direct target of SRF/MYOCD. To test this hypothesis, we first evaluated whether MYOSLID is induced by MKL1, a MYOCD-related transcription factor family member whose function on VSMC differentiation is also associated with SRF/CArG. 28 Similar to MYOCD, overexpression of MKL1 caused a 40-fold increase of MYOSLID expression in HCASMCs ( Figure 3A ). Importantly, knockdown of MYOCD by siRNA resulted in significant downregulation of MYOSLID ( Figure 3B) . Surprisingly, depletion of endogenous SRF by siRNA had little effect on MYOSLID expression under basal conditions. However, SRF knockdown attenuated the induction of MYOSLID by MYOCD, indicating that MYOCD induction of MYOSLID expression requires normal SRF levels ( Figure 3C ).
To further delineate the transcriptional regulation of MYOSLID, we PCR cloned the −2 kb promoter of MYOSLID into a luciferase reporter plasmid. This −2 kb MYOSLID luciferase reporter showed significant promoter activity compared with control vector in SKLMS, a human uterine leiomyosarcoma cell line, which expresses similar markers of the contractile state as VSMCs ( Figure 3D ). Both MYOCD and SRF activated the −2 kb promoter in SKLMS ( Figure 3E and 3F) and HEK293 cells (data not shown), providing evidence for CArG-dependent transactivation. Chromatin immunoprecipitation assay with SRF antibody in HCASMCs revealed significant enrichment of the DNA flanking each of the predicted CArG boxes. In contrast, no obvious enrichment was seen in a negative control region of exon 3 where no predicted CArG box resides ( Figure 3G , left), indicating the specificity of the binding between SRF and CArG. SRF binding to CArG boxes near MYOSLID was less than that seen in the intronic CArG1 (IC1) of CNN1 likely because of the greater affinity of SRF for the consensus CArG in CNN1 versus nonconsensus CArGs near MYOSLID (Figure 3G , right). 29 To ascertain whether specific CArG boxes are critical for MYOCD transactivation, we constructed 2 truncated luciferase reporters and compared their response to MYOCD with the original −2 kb reporter. The −2 kb reporter encompassing 3 putative CArG boxes displayed the highest response to MYOCD. The truncated −890 bp reporter harboring CArG2/ CArG3 showed a significantly reduced response to MYOCD. The −157 bp reporter lacking all 3 predicted CArG boxes was barely activated by MYOCD ( Figure 3H ). Collectively, these data support MYOSLID as a new direct transcriptional target of the MYOCD/SRF/CArG triad.
MYOSLID Is an Activator of the VSMC Contractile Phenotype
Having demonstrated MYOSLID as a direct transcriptional target of MYOCD/SRF, we sought to explore the association of MYOSLID with VSMC differentiation. Similar to ACTA2 or CNN1, MYOSLID was significantly downregulated with PDGF, tumor necrosis factor-α, and interleukin-1β treatment ( Figure 4A and 4B). However, MYOSLID was induced on stimulation with TGFβ1, a potent activator of human VSMC differentiation 30 ( Figure 4C ). To determine whether MYOSLID is associated with vascular disease, we assessed MYOSLID levels by qRT-PCR in discarded and failed human arteriovenous fistula (AVF) samples from patients with end-stage renal disease. The hyperplastic and stenotic response associated with AVF failure is thought to involve SMC dedifferentiation. 31 Similar to MYH11, the gold standard marker of the contractile VSMC phenotype, levels of MYOSLID were reduced in failed AVF specimens compared with normal control vein samples obtained at the time of AVF creation ( Figure 4D ). Although no significant difference of SRF mRNA was seen between 26 These data suggest that MYOSLID is a new member of the SRF-dependent program of human VSMC differentiation and, like other differentiation marker genes, is reduced under pathological conditions, promoting VSMC dedifferentiation. The association of MYOSLID expression with the differentiated VSMC phenotype prompted us to investigate whether MYOSLID confers a regulatory role in VSMC differentiation. Two D-siRNAs targeting different regions of the MYOSLID transcript achieved >80% knockdown efficiency in HCASMCs ( Figure 4E ). Depletion of MYOSLID resulted in significant decreases in mRNA levels of VSMC contractile genes under both basal and TGFβ1-induced conditions; no consistent effect was seen for SRF or MYOCD ( Figure 4E ). Western blotting validated the downregulation of VSMC contractile proteins on knockdown of MYOSLID in HCASMCs ( Figure 4F ). We also demonstrated downregulation of the contractile proteins with a third D-siRNA to MYOSLID (data not shown). caused a modest but significant increase in the mRNA levels of most VSMC genes, such as ACTA2, CNN1, and TAGLN. This change was not applied to every gene because IL6 mRNA was reduced when MYOSLID_V1 was overexpressed ( Figure 4G ), suggesting the effect of overexpression of MYOSLID_V1 is specific to VSMC contractile genes. Western blot confirmed that protein levels of CNN1 and ACTA2 were also induced when MYOSLID_V1 was overexpressed ( Figure 4H ). Overexpression of MYOSLID_V1 increased TAGLN protein in basal conditions but not in TGFβ1-induced conditions, which is likely because of the fact that the strong induction of TAGLN protein exerted by TGFβ1 masks the effect of MYOSLID overexpression. Because differentiated VSMCs display less cell proliferation, we tested whether overexpression of MYOSLID_V1 could suppress growth and migration of HCASMCs. Indeed, lentiviral transduction of MYOSLID_V1 in serum-stimulated HCASMCs attenuated cell proliferation ( Figure 4I ) and migration ( Figure 
Conversely, overexpression of MYOSLID_V1 in HCASMCs
Depletion of MYOSLID Disrupts Stress Fiber Assembly and Inhibits TGFβ1-Induced MKL1 Nuclear Translocation
Depletion of MYOSLID resulted in an obvious disruption of stress fiber assembly visualized by F-actin staining in HCASMCs ( Figure 5A ). It has been established that MKL1 cellular shuttling and downstream SRF-dependent gene expression are tightly regulated by actin dynamics. 32, 33 Accordingly, we considered the possibility that MYOSLID might affect MKL1 nucleocytoplasmic shuttling, and thus transcriptional activation of VSMC contractile genes, through the effects of MYOSLID on the actin cytoskeleton.
To test this hypothesis, MYOSLID expression was depleted with siRNA in HCASMCs followed by TGFβ1 treatment to stimulate nuclear translocation of MKL1. 34 F-actin assembly was disrupted on MYOSLID knockdown in both vehicle and TGFβ1-treated groups ( Figure 5B ). Furthermore, forced expression of MYOSLID_V1 rescued F-actin formation in HCASMCs when SRF was depleted although no obvious differences were seen under the basal conditions ( Figure VI in the online-only Data Supplement). Under unstimulated conditions, MKL1 was distributed in both cytosolic and nuclear fractions of control D-siRNA and D-siMYOSLID-treated HCASMCs. TGFβ1 promoted a striking nuclear translocation of MKL1 in the control D-siRNA-treated cells; however, this nuclear shuttling was attenuated on knockdown of MYOSLID ( Figure 5B ). Quantitative analysis demonstrated that ≈75% of control D-siRNA-treated cells had exclusively nuclear MKL1, and a small portion (25%) of cells showed both cytosolic and nuclear distribution of MKL1 after TGFβ1 treatment ( Figure 5C ). Conversely, the majority of cells (≈75%) from the D-siMYOSLID-treated group failed to undergo TGFβ1-induced MKL1 nuclear translocation because MKL1 was retained in both cytosolic and nuclear compartments with only 25% of the cells exhibiting nuclear MKL1 ( Figure 5C ). D-siMYOSLID-treated cells displayed a significantly lower ratio of nuclear to cytosolic MKL1 content compared with the control D-siRNA-treated cells ( Figure 5D ), providing further evidence that depletion of MYOSLID attenuated MKL1 nuclear shuttling. Taken together, these data suggest that MYOSLID promotes F-actin assembly leading to MKL1 nuclear translocation and the subsequent transcriptional activation of downstream VSMC contractile genes.
A Positive Feedback Loop Between TGFβ1/ SMAD Pathway and MYOSLID
Like most VSMC-specific genes, MYOSLID is also induced by TGFβ1 ( Figure 4C ). Sequence analysis of the −2 kb MYOSLID promoter indicated 3 putative SMAD-binding elements ( Figure 6A ), suggesting that MYOSLID could be a direct transcriptional target of the classical TGFβ1/SMAD pathway as seen with the miR-143/145 locus. 30 As expected, luciferase assay revealed that TGFβ1 induced a 4-fold increase in MYOSLID promoter activity, whereas this activation was significantly attenuated when all 3 SMAD-binding elements were mutated ( Figure 6B ), suggesting that TGFβ1 activates MYOSLID promoter via ≥1 of these 3 SMAD-binding elements. Consistent with the luciferase data, knockdown of endogenous SMAD4, the common mediator SMAD (co-SMAD), reduced the basal level of MYOSLID and abolished TGFβ1-induced upregulation of MYOSLID ( Figure 6C ). On the basis of these data, we conclude that MYOSLID is a direct transcriptional target of the classical TGFβ1/SMAD pathway. We next sought to evaluate the effect of loss of MYOSLID on SMAD2 activation, a key process for TGFβ1/SMAD in transactivating VSMC gene expression. 35 Depletion of MYOSLID significantly decreased TGFβ1-induced SMAD2 phosphorylation at both 1 and 7 hours after TGFβ1 treatment in HCASMCs ( Figure 6D) . These data indicate a positive feedback loop between TGFβ1/SMAD and MYOSLID in regulating VMSC contractile gene expression.
Discussion
The human genome undergoes pervasive transcription, thus debunking the traditional view of widespread junk DNA. 36 LncRNAs, the byproduct of much transcription in the genome, are emerging as critical regulators of virtually every aspect of VSMC biology. 23 Here, we report MYOSLID as the first CArG-SRF-MYOCD-dependent lncRNA. MYOSLID seems to amplify the VSMC contractile program through an effect on 2 parallel pathways ( Figure 6E ). Loss of MYOSLID disrupts F-actin assembly, a key process governing MKL1 nuclear shuttling, which is necessary for MKL1 to transactivate VSMC contractile genes.
A D E B C Figure 6 . A positive feedback loop between transforming growth factor-β1 (TGFβ1)/SMAD and MYOSLID and a working model of MYOSLID in vascular smooth muscle cells (VSMCs). A, Schematic diagram for the 3 computer-predicted SMAD binding elements (SBEs, denoted as S1, S2, and S3, respectively) within the −2 kb MYOSLID promoter and the mutagenesis strategy of the SBEs. B, The −2 kb MYOSLID wild-type (WT) luciferase reporter and its SBE mutant (with all three SBEs mutated) were transfected in 10T1/2 cells. Cells were starved overnight and then stimulated by TGFβ1 (5 ng/mL) for 24 h before luciferase activity assessment. The TGFβ1 activation was defined as fold increase to the vehicle treated control group (set to 1). Representative data from multiple independent experiments (n≥3) were expressed as the average of triplicates. C, Human coronary arterial smooth muscle cells (HCASMCs) were transfected with siRNA to SMAD4 (siSMAD4) for 24 h, cells were then starved overnight followed by treatment with TGFβ1 (4 ng/mL) for another 24 h before RNA extraction for quantitative reverse transcription polymerase chain reaction analysis of the indicated genes. D, HCASMCs were transfected with the indicated D-siMYOSLID for 24 h, cells were then starved overnight followed by the treatment of TGFβ1 (4 ng/mL) for the indicated time. Western blot was done for the analysis of the indicated proteins. Data were representative of 3 separate experiments. E, Schematic model illustrating the regulation and the functional roles of MYOSLID in VSMCs: 2 parallel pathways, MYOCD-related transcription factor A (MKL1)/serum response factor (SRF) and TGFβ1/SMAD, are critical to transcriptionally regulate MYOSLID in VSMCs; MYOSLID works with both pathways in a feed-forward fashion to amplify VSMC differentiation. Solid lines represent the pathways suggested by the experimental evidence reported here and the hypothetical unknown pathway is indicated with dotted lines.
Accordingly, loss of MYOSLID blocks TGFβ1-induced MKL1 nuclear translocation, implicating a novel mechanism through which MYOSLID may function to amplify VSMC contractile gene expression. Furthermore, TGFβ1/SMAD, a critical regulatory pathway for VSMC development and differentiation, 35, 37 directly transactivates MYOSLID. Reduced expression of MYOSLID attenuates TGFβ1-induced SMAD2 phosphorylation, indicating a positive feedback loop between TGFβ1/SMAD and MYOSLID in regulating VSMC differentiation. Because decreased MYOSLID is seen in the human failed AVF samples where VSMC differentiation is compromised, our results imply that loss of MYOSLID may play an important role in the vascular remodeling underlying the pathogenesis of vascular diseases. We surmise such loss in expression of MYOSLID is because of attenuated expression of MYOCD. MYOCD is necessary and sufficient for driving a VSMC contractile phenotype through the induction of VSMC-specific contractile genes and regulatory microRNAs. 26 Because the vast majority of transcripts from the genome are lncRNAs, with >100 000 to date, 15 we predicted there must be MYOCD regulated lncRNAs that augment or attenuate the VSMC contractile gene program. Indeed, RNA-seq in HCASMC revealed >100 lncRNAs that are significantly regulated by MYOCD. Interestingly, careful analysis of 13 human MYOCD-lncRNAs revealed that all transcripts are only conserved in primates, such as Rhesus monkey and Chimp, which is in agreement with the poorly conserved characteristic of most lncRNAs. 38 Although MYOSLID lacks sequence conservation in rodents, it will be interesting to see whether it possesses a conserved secondary structure, which might confer functional conservation in rodents. These human-and primate-specific MYOCD-lncRNAs may render unique biological features to SMCs directly related to the pathogenesis of vascular diseases in humans. Therefore, elucidation of the regulation and functionality of MYOCD-lncRNAs will provide novel insights into the biology of MYOCD-dependent processes in VSMCs with high translational significance.
Thus far, several lncRNAs have been reported to differentially modulate VSMC proliferation, apoptosis, migration, and differentiation 17, 25, 39 and, among these, ANRIL and LincRNA-p21 have been suggested to regulate the progression of atherosclerosis. 25, 39 However, these lncRNAs display a broad spectrum expression profile, which could be a potential obstacle for their clinical application. In contrast, MYOSLID is a VSMC-selective positive regulator of the VSMC differentiation program via promoting contractile gene expression and suppressing VSMC proliferation and migration. This result is consistent with data showing MYOSLID is induced by MYOCD and reduced in failed human AVF samples wherein the contractile VSMCs phenotypically switch to the synthetic state. We confirmed the knockdown effect of MYOSLID on contractile gene expression with multiple siRNAs in different HCASMC isolates, indicating MYOSLID is necessary for a fully executed VSMC contractile gene program. Of note, MYOSLID does not affect the gene expression of MYOCD, the molecular switch for the VSMC differentiation program 6 ( Figure 4E ). Furthermore, there was no consistent effect of MYOSLID on SRF or MKL1 ( Figure 4E ; Figure VIIA in the online-only Data Supplement), indicating the effect of MYOSLID on the downstream contractile gene expression is not attributed to altered gene expression of these regulators of the SMC contractile phenotype. Interestingly, overexpression of MYOSLID in non-SMC systems (such as HEK293 cells and BR5 fibroblast cells) was unable to induce contractile gene expression (data not shown), indicating the effect of MYOSLID on VSMC contractile gene expression is cell context dependent and may only be restricted to VSMC. Thus, we do not consider MYOSLID as a master regulator of VSMC differentiation in the sense of MYOCD or the recent chromatin remodeling factor ten-eleven translocation-2. 40 Given that MYOSLID is a VSMC-selective lncRNA that apparently amplifies the VSMC differentiation program, it could hold potential as a therapeutic target for treating vascular diseases.
MYOSLID is a direct transcriptional target of both MYOCD/SRF and TGFβ1/SMAD pathways, similar to miR143/145. 30 Moreover, depletion of SMAD4 totally abolished TGFβ1-induced MYOSLID expression, indicating that the induction of MYOSLID by TGFβ1 is solely through the classical SMAD pathway, which is probably because of the transient induction of MYOCD by TGFβ1 in HCASMCs. 30 Of note, 3 functionally active CArG boxes in the proximal promoter region of MYOSLID are not conserved in mouse, in keeping with the absence of a true ortholog of MYOSLID in mouse. By contrast, SENCR, a vascular cell-enriched lncRNA that also positively regulates the VSMC differentiation program 17 is a MYOCD/SRF-independent lncRNA, despite the presence of several conserved CArG boxes in the proximal promoter (J.M. Miano, unpublished data, 2015) . This underscores the fact that not every predicted CArG box is functional, especially those deviating from the consensus sequence whose SRF-binding affinity is normally weak. There are thousands of conserved CArG boxes in the human genome 41 and >100 000 lncRNAs annotated in the human genome. 15 A big challenge, therefore, will be to identify additional SRF/CArG dependent and human-specific lncRNAs from the vast sea of lncRNAs through the integration of high throughput sequencing experiments, comprehensive bioinformatics analysis of CArG boxes, and SRF chromatin immunoprecipitation-seq studies.
A notable paradigm to emerge from this study is the putative positive feedback loop between MYOSLID and TGFβ/SMAD, implying a novel mechanism in the regulation of MYOSLID on VSMC differentiation. The classical SMAD-dependent pathway, which necessitates the phosphorylation of SMAD transcription factors for its subsequent nuclear translocation, DNA-binding and ultimate transcriptional activation, has been demonstrated as an important pathway in vascular development and VSMC differentiation. 35, 42 We found that depletion of MYOSLID decreases SMAD2 phosphorylation, indicating that MYOSLID is critical in the activation of SMAD and subsequent VSMC transcription. Inspired by the recent publications showing cytosolic lncRNAs influence the phosphorylation of signal proteins or transcription factors via direct physical association, 21, 22 we attempted to detect the physical interaction between MYOSLID and SMAD2. However, both in vitro RNA pulldown and in vivo RNA precipitation assays have thus far failed to reveal such a physical interaction (data not shown). This may be attributed to ≥1 of the following facts: first, the interaction may be transient or weak and, therefore, difficult to establish with the assays used; second, the effect of MYOSLID on SMAD2 phosphorylation may be an indirect phenomenon, involving unknown interactive partners. Thus, the mechanism through which MYOSLID influences SMAD2 phosphorylation needs to be further investigated with more sophisticated tools in RNA biology.
Actin dynamics are intimately linked to nuclear gene transcription, primarily through MKL1 nucleocytoplasmic shuttling. 32, 33 In the static state, MKL1 binds G-actin and, thus, is retained in the cytoplasm. On G-actin polymerization, MKL1 is released and translocates to the nucleus where it binds SRF over CArG-dependent target genes. 32, 33 We found that depletion of MYOSLID can disrupt F-actin formation and block TGFβ1-induced MKL1 nuclear translocation. Furthermore, forced expression of MYOSLID can rescue F-actin formation in VSMCs when SRF is depleted. We hypothesize that MYOSLID might affect the signal pathway(s), which is essential for F-actin assembly. F-actin formation is governed mainly by the upstream regulators of Rho family GTPases. 32 Therefore, it will be important to examine whether MYOSLID can directly interact with Rho family GTPases and affect their activity.
The full-fledged VSMC contractile phenotype is orchestrated by a closely interactive network of transcription factors, microRNAs, and signal transducers. 13, 23, 43 The emergence of lncRNAs in VSMCs renders this network even more comprehensive. However, given that MYOSLID is primarily localized in the cytosol, it is unlikely that MYOSLID directly influences the transactivation of SRF/MYOCD by physically interacting with them or affecting chromatin remodeling. Furthermore, although a pathway involving a competing endogenous (sponge) RNA titrating a microRNA of VSMC differentiation (such as miR1) from its target transcript (such as MYOCD) is an attractive mechanism for MYOSLID to execute its positive role in governing VSMC differentiation, analysis of data from the LNCipedia database did not reveal any potential seed sequences corresponding to known microRNAs within the MYOSLID transcript (unpublished data). In line with this, MYOSLID has little to no effect on MYOCD expression. We recently reported that SENCR is a vascular cell-enriched lncRNA that stabilizes the VSMC contractile phenotype. 17 Although both MYOSLID and SENCR seem to act as positive regulators of VSMC contractile phenotype, depletion of MYOSLID has no effect on SENCR expression ( Figure VIIB in the online-only Data Supplement). Therefore, the effect of MYOSLID on VSMC differentiation does not seem to be associated with SENCR expression. Knockdown of SENCR can decrease MYOCD gene expression, suggesting the regulation of SENCR on VSMC differentiation is likely through MYOCD expression. However, this effect was not seen with MYOSLID ( Figure 4E ). Altogether, we surmise that MYOSLID and SENCR may use their own distinct mechanisms in augmenting the VSMC contractile phenotype.
In summary, we report an array of lncRNAs regulated by MYOCD, which we refer to as MYOCD-lncRNAs. We demonstrated that one of these MYOCD-lncRNAs, MYOSLID, is VSMC-selective, SRF/CArG dependent, and an amplifier of the VSMC differentiation program, likely through the effects on MKL1 nuclear translocation and activation of the TGFβ/ SMAD pathway. These studies, together with our previous findings with SENCR, imply that VSMC lncRNAs constitute a new layer of molecular regulation of the differentiated VSMC phenotype.
